The U.S. Army Medical Materiel Development Activity is the Department of Defense's (DOD) medical product development activity for products designed to protect and preserve the lives of Warfighters. The USAMMDA develops new drugs, vaccines, devices, and medical support equipment that enhance readiness, ensures the provision of the highest quality medical care to the DOD, and maximizes survival of medical casualties on the battlefield.
USAMMDA project managers guide the development of medical products for the U.S. Army Medical Department, other U.S. Services, the Joint Staff, the Defense Health Agency, and U.S. Special Forces community. The process takes promising technology from DOD, industry, and academia to U.S. Forces, from the testing required for U.S. Food and Drug Administration (FDA) approval or licensing, to fielding and sustainment of the finished product.
The USAMMDA accomplishes its mission by exercising two core capabilities:
- Program management for USAMRDC medical product development projects, and
- Serving as the Army Surgeon General's Lead Component for Investigational New Drug (IND) treatment, prophylaxis and diagnostic capabilities.
USAMMDA is a subordinate activity under U.S. Army Medical Research and Development Command (USAMRDC) supporting the Command as the primary advanced development medical research, development, and acquisition organization within DOD and is responsible for meeting medical developmental requirements from both the Army and other military services.